OBJECTIVE: To determine the prevalence of human papillomavirus (HPV) DNA in cervical specimens from treatment-naive women initiating highly active antiretroviral therapy (HAART) and explore the longitudinal association of HPV DNA with CD4 count and HIV viral load (VL). METHODS: Women enrolled before HAART were evaluated at baseline, weeks 24, 48, and 96 with CD4 count, VL, and cervical swab for HPV DNA. RESULTS: The 146 subjects had a median CD4 count of 238 cells per microliter and VL of 13,894 copies per milliliter. Ninety-seven subjects (66%) had HPV DNA detected in the baseline specimen including 90 subjects (62%) positive for 1 or more high-risk HPV types. HPV DNA detection declined to 49% at week 96 and that of a high risk HPV type to 39%. The duration of follow-up was associated with decreased detection of HPV DNA of any type (P = 0.045) and of high-risk HPV types (P = 0.003). There was at most a marginal association between HAART response and loss of detection of cervical HPV DNA. CONCLUSIONS: Women initiating HAART had a high prevalence of cervical HPV DNA that declined over 96 weeks of HAART. The relationship of CD4 count and VL response to the decline of cervical HPV DNA was not strong.
OBJECTIVE: To determine the prevalence of human papillomavirus (HPV) DNA in cervical specimens from treatment-naive women initiating highly active antiretroviral therapy (HAART) and explore the longitudinal association of HPV DNA with CD4 count and HIV viral load (VL). METHODS:Women enrolled before HAART were evaluated at baseline, weeks 24, 48, and 96 with CD4 count, VL, and cervical swab for HPV DNA. RESULTS: The 146 subjects had a median CD4 count of 238 cells per microliter and VL of 13,894 copies per milliliter. Ninety-seven subjects (66%) had HPV DNA detected in the baseline specimen including 90 subjects (62%) positive for 1 or more high-risk HPV types. HPV DNA detection declined to 49% at week 96 and that of a high risk HPV type to 39%. The duration of follow-up was associated with decreased detection of HPV DNA of any type (P = 0.045) and of high-risk HPV types (P = 0.003). There was at most a marginal association between HAART response and loss of detection of cervical HPV DNA. CONCLUSIONS:Women initiating HAART had a high prevalence of cervical HPV DNA that declined over 96 weeks of HAART. The relationship of CD4 count and VL response to the decline of cervical HPV DNA was not strong.
Authors: P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple Journal: J Clin Microbiol Date: 2000-01 Impact factor: 5.948
Authors: H Minkoff; L Ahdieh; L S Massad; K Anastos; D H Watts; S Melnick; L Muderspach; R Burk; J Palefsky Journal: AIDS Date: 2001-11-09 Impact factor: 4.177
Authors: R W Coombs; D J Wright; P S Reichelderfer; D N Burns; J Cohn; S Cu-Uvin; P A Baron; M H Cohen; A L Landay; S Lewis; A Kovacs Journal: J Infect Dis Date: 2001-09-13 Impact factor: 5.226
Authors: F B Lillo; D Ferrari; F Veglia; M Origoni; M A Grasso; S Lodini; E Mastrorilli; G Taccagni; A Lazzarin; C Uberti-Foppa Journal: J Infect Dis Date: 2001-08-09 Impact factor: 5.226
Authors: Denise J Jamieson; Ann Duerr; Robert Burk; Robert S Klein; Pangaja Paramsothy; Paula Schuman; Susan Cu-Uvin; Keerti Shah Journal: Am J Obstet Gynecol Date: 2002-01 Impact factor: 8.661
Authors: M C Delmas; C Larsen; B van Benthem; F F Hamers; C Bergeron; J D Poveda; B Anzén; A van den Hoek; F Meier; J M Peña; H Savonius; D Sperandeo; B Suligoi; P Vernazza; J B Brunet Journal: AIDS Date: 2000-08-18 Impact factor: 4.177
Authors: L Ahdieh; R S Klein; R Burk; S Cu-Uvin; P Schuman; A Duerr; M Safaeian; J Astemborski; R Daniel; K Shah Journal: J Infect Dis Date: 2001-08-24 Impact factor: 5.226
Authors: Diane Solomon; Diane Davey; Robert Kurman; Ann Moriarty; Dennis O'Connor; Marianne Prey; Stephen Raab; Mark Sherman; David Wilbur; Thomas Wright; Nancy Young Journal: JAMA Date: 2002-04-24 Impact factor: 56.272
Authors: Pangaja Paramsothy; Denise J Jamieson; Charles M Heilig; Paula C Schuman; Robert S Klein; Keerti V Shah; Anne M Rompalo; Susan Cu-Uvin; Ann Duerr Journal: Obstet Gynecol Date: 2009-01 Impact factor: 7.661
Authors: Hung N Luu; E Susan Amirian; Wenyaw Chan; R Palmer Beasley; Linda B Piller; Michael E Scheurer Journal: J Infect Dis Date: 2012-01-13 Impact factor: 5.226
Authors: Michelle S Cespedes; Sarah L Kerns; Robert S Holzman; Paul J McLaren; Harry Ostrer; Judith A Aberg Journal: HIV Clin Trials Date: 2013 Nov-Dec
Authors: Jessica A Kahn; Robert D Burk; Kathleen E Squires; Bill G Kapogiannis; Bret Rudy; Jiahong Xu; René Gonin; Nancy Liu; Carol Worrell; Craig M Wilson Journal: J Acquir Immune Defic Syndr Date: 2012-11-01 Impact factor: 3.731
Authors: R A Hanisch; P S Sow; M Toure; A Dem; B Dembele; P Toure; R L Winer; J P Hughes; G S Gottlieb; Q Feng; N B Kiviat; S E Hawes Journal: J Clin Virol Date: 2013-10-18 Impact factor: 3.168